双嘧达莫对淋巴瘤患者外周血PAC-1和CD62p影响的初步观察  

Initial observation of dipyridamole influence on PAC-1 and CD62p expressions in lymphoma patients

作　　者：江亚军[1] 李秀梅[1] 王红霞[2] 韩秀华[1] 朱贵华[1] 庄万传[1] 何耀[1] 

机构地区：[1]连云港市第二人民医院血液科,江苏连云港222002 [2]连云港市第一人民医院病理科,江苏连云港222002

出　　处：《中华肿瘤防治杂志》2010年第24期2035-2037,2044,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:研究双嘧达莫对淋巴瘤患者外周血血小板活化标志PAC-1和CD62p表达水平及近期疗效的影响。方法:选择42例淋巴瘤患者随机分为单纯化疗组(单纯组)和化疗+双嘧达莫组(联合组)。联合组患者在化疗基础上应用双嘧达莫100 mg/d;另选择15名健康体检者作为对照组。应用流式细胞术(FCM)分别于化疗d0、d3、d7及d14检测淋巴瘤患者外周血血小板PAC-1和CD62p的表达水平。结果:1)淋巴瘤患者外周血PAC-1和CD62p表达水平较对照组明显升高,P<0.01。2)单纯组在化疗d0、d3的PAC-1表达较化疗d14明显升高,P<0.05和0.01;化疗d3的CD62p表达较化疗d0、d14明显增高,P<0.01。联合组在化疗d14的PAC-1表达水平较化疗d0、d3明显降低,P<0.01;化疗d14的CD62p表达较化疗d0、d3降低,P<0.05和0.01。3)联合组在化疗d7、d14的PAC-1以及化疗d3、d7、d14的CD62p与单纯组比较表达下降,P<0.05和0.01。4)治疗4个周期后单纯组和联合组总缓解率(CR+PR)分别为78.95%(15/19)和82.35%(14/17),两组间近期疗效比较差异无统计学意义,χ2=1.204,P>0.05。结论:淋巴瘤患者常出现外周血小板活化,双嘧达莫能有效地抑制患者外周血PAC-1和CD62p表达,从而抑制血小板的活化。OBJECTIVE：To study the influence of dipyridamole on the expressions of platelet activated markers PAC-1 and CD62p and the short-term efficacy of lymphoma patients.METHODS：A total of 42 lymphoma patients were divided into a simple chemotherapy group（simple group） and a chemotherapy add dipyridamole group（combined group） randomly,and 15 healthy subjects were selected as a control group.One hundred mg dipyridamole was added to the patients in the combined group per day.The expressions of PAC-1 and CD62p were detected by flow cytometry（FCM） at d0,d3,d7 and d14 in chemotherapy cycle respectively.RESULTS：1）The levels of PAC-1 and CD62p in lymphoma patients were significantly higher than those in the control group（both P〈0.01）.2）The PAC-1 expressions at d0 and d3 in the simple group were higher than that at d14（P〈0.05,P〈0.01）,and the CD62p level at d3 was higher than those at d0 and d14 in chemotherapy cycle（bothP〈0.01）.The PAC-1 expression in the combined group at d14 was lower than those at d0 and d3（bothP〈0.01）,and the CD62p at d14 was lower than those at d0 and d3 in chemotherapy cycle（P〈0.05,P〈0.01）.3）The PAC-1 and CD62p expressions in the combined group at d3,d7 and d14 were lower than those in the simple group.4）The total remission rates（CR＋PR） of the simple group and combined group were 78.95%（15/19） and 82.35%（14/17） respectively after four chemotherapy cycles,and no significance was found between their short-term efficacies（χ^2=1.204,P〈0.05）.CONCLUSION：Lymphoma patients usually accompany with platelet activation in peripheral blood and dipyridamole can restrain PAC-1 and CD62p expressions efficiently to inhibit platelet activation.

关 键 词：淋巴瘤 血小板活化 PAC-1 CD62P 双嘧达莫 流式细胞术 

分 类 号：R733.1[医药卫生—肿瘤]